Verici Dx raises £8.5M in oversubscribed placing at steep discount
What's the deal? Verici DxDealroom has a profile for this one. Try Dealroom → (AIM: VRCI), a developer of clinical diagnostics for organ transplantation, has conditionally raised £8.5 million by placing 4,250,000,000 new shares at 0.20p each. The post-IPO equity raise was upsized from its initial target after an accelerated bookbuild drew demand from existing and new institutional investors.
The terms: The 0.20p issue price is an 11.1% discount to the 0.225p closing price on September 30, 2026 — the last trading day before shares were suspended for a Capital Access Window. Singer Capital MarketsDealroom has a profile for this one. Try Dealroom → and Oberon CapitalDealroom has a profile for this one. Try Dealroom → acted as joint brokers and bookrunners.
How it splits: The placing includes roughly 1,683,000,000 Firm Placing Shares and 2,567,000,000 Conditional Placing Shares. Firm shares are set to begin trading on AIM on October 13, 2026; the conditional tranche requires shareholder approval at a General Meeting, with admission expected around October 28.
Verici Dx also plans a retail offer through the Winterflood Retail Access PlatformDealroom has a profile for this one. Try Dealroom →, aiming to raise up to a further £250,000 at the same 0.20p price.
Director participation: Two directors subscribed directly. Chairman Julian Baines bought 10,000,000 shares, lifting his holding to 18,548,482. Chief executive officer Sara Barrington subscribed for 5,000,000 shares, raising her stake to 13,285,715.
What could go wrong? Completing the full £8.5 million depends on shareholders approving the issue of the 2,567,000,000 Conditional Placing Shares. Until then, only the Firm Placing Shares will be admitted. A failed vote would block the Second Admission and cap the capital available for Verici Dx's diagnostics development.
The signal: Upsizing the round to meet demand, paired with direct buying from the chairman and chief executive officer, points to investor appetite despite the discount and the two-stage structure. All new shares rank pari passu with existing ordinary shares, including rights to future dividends.
Read more: kalkinemedia.com
Image credit: Tareq Salahuddin
